Jonathan P. DiVincenzo, President and Chief Operating Officer of Bio-Rad Laboratories, Inc., filed a Form 4 on October 25, 2026, reporting the vesting of restricted stock units and a related tax-withholding disposition of Bio-Rad Class A common stock on October 24, 2026.

Key Highlights

  • RSU vesting: 1,869 restricted stock units converted into 1,869 shares of Bio-Rad Class A common stock on October 24, 2026, at a price of $0.
  • Tax withholding disposition: 951 shares were disposed of on October 24, 2026, at $369.95 per share to satisfy tax obligations (transaction code F).
  • Remaining direct holdings: DiVincenzo directly holds 2,881 shares of Bio-Rad Class A common stock following the reported transactions.
  • Remaining RSU balance: 3,740 restricted stock units remain beneficially owned directly after the vesting event.
  • Vesting schedule: According to the filing, the restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
  • Reporting person role: DiVincenzo is identified in the filing as President and COO of Bio-Rad Laboratories, Inc., traded under tickers BIO and BIO.B.

DiVincenzo RSU Vesting and Share Withholding Details

According to the filing, Jonathan P. DiVincenzo, President and Chief Operating Officer of Bio-Rad Laboratories, Inc. (NYSE:BIO), reported two transactions in Bio-Rad Class A common stock on October 24, 2026. The first was the acquisition of 1,869 shares through the vesting of restricted stock units (transaction code M) at a price of $0. The filing notes that these shares were "acquired on the vesting of restricted stock units."

The second transaction was the disposition of 951 shares (transaction code F) at $369.95 per share. This type of transaction is commonly reported in connection with the withholding of shares to cover tax obligations upon vesting, though the filing describes it only as a disposition coded F. Following both transactions, DiVincenzo directly holds 2,881 shares of Bio-Rad Class A common stock, the filing states.

On the derivative securities side, the filing reports that 1,869 restricted stock units were settled via the M-coded transaction, reducing DiVincenzo's outstanding RSU balance. Each restricted stock unit, according to the filing, "represents a contingent right to receive one share of Bio-Rad Class A common stock," and the units vest over four years at 25% per year on the yearly anniversary of the grant date. After the vesting, 3,740 restricted stock units remain directly held by DiVincenzo, according to the filing.

What Was Disclosed

The Form 4 filed October 25, 2026, discloses that Bio-Rad Laboratories President and COO Jonathan P. DiVincenzo acquired 1,869 shares via RSU vesting and disposed of 951 shares at $369.95 on October 24, 2026, leaving him with 2,881 shares and 3,740 unvested RSUs.